Inside the research
Krystal Biotech, Inc.
KRYS Research profile · latest available data
Price overview
$345.82
▲ +0.86 (+0.2%)
| 52w hi | $378.15 |
|---|---|
| 52w lo | $161.15 |
| Vol | 200.00K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.13
| Short | -0.06 |
|---|---|
| Medium | +0.24 |
| Long | +0.31 |
computed 2026-09-27
Key fundamentals
Krystal Biotech, Inc.
Healthcare · Biotechnology
| Market cap | $10.24B |
|---|---|
| Enterprise value | $9.40B |
| Trailing P/E | 43.28x |
| Forward P/E | 37.11x |
| EV / EBITDA | 47.16x |
| P / S (ttm) | 23.24x |
| Profit margin | 54.8% |
| Return on equity | 20.1% |
| Revenue growth | +24.1% |
| Earnings growth | +38.8% |
| Debt / equity | 0.65 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.26 | |
| Sector | +0.08 | |
| Technical | -0.01 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Risk Metrics
| Beta vs SPX | 0.86 |
|---|---|
| Corr SPX | 0.33 |
| Annual vol | 41.7% |
| Annual ret | +40.3% |
| Sharpe | 0.97 |
| Max DD | -38.2% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $318.22 |
|---|---|
| High / Low | $399.00 / $241.00 |
| Median | $310.00 |
| Analysts | 9 |
| Strong Buy | 0 | |
|---|---|---|
| Buy | 10 | |
| Hold | 1 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-05 | Evercore ISI Group | → Outperform |
| 2026-05-05 | Citigroup | → Buy |
| 2026-05-04 | HC Wainwright & Co. | → Buy |
| 2026-03-27 | Wolfe Research | → Peer Perform |
| 2026-02-25 | Guggenheim | → Buy |
| 2026-02-18 | Citigroup | → Buy |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-03 | Earnings Release, Exhibits | read |
| 2026-07-21 | Other Material Event, Exhibits | read |
| 2026-05-20 | Shareholder Vote | read |
| 2026-05-04 | Exhibits | read |
| 2026-02-17 | Earnings Release | read |
| 2026-01-12 | Earnings Release, Reg FD Disclosure… | read |
| 2026-01-08 | Reg FD Disclosure, Exhibits | read |
| 2025-12-23 | Officer / Director Change, Exhibits | read |
| 2025-11-03 | Earnings Release | read |
| 2025-10-22 | Other Material Event | read |
| 2025-08-04 | Earnings Release, Exhibits | read |
| 2025-07-25 | Reg FD Disclosure | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-14 | ROSSI DINO A | Gift | 3.69K | — | |
| 2026-08-14 | ROSSI DINO A | Sell | 2.29K | $746.94K | |
| 2026-08-14 | ROSSI DINO A | Sell | 5.23K | $1.71M | |
| 2026-08-14 | ROSSI DINO A | Sell | 341 | $111.03K | |
| 2026-08-14 | ROSSI DINO A | Sell | 7.43K | $2.45M | |
| 2026-08-14 | ROSSI DINO A | Sell | 4.90K | $1.62M | |
| 2026-08-14 | ROSSI DINO A | Sell | 3.10K | $1.03M | |
| 2026-08-14 | ROSSI DINO A | Sell | 40 | $13.33K | |
| 2026-08-14 | ROSSI DINO A | Sell | 1.69K | $554.21K | |
| 2026-06-25 | Thomas John Charles | EVP, General Counsel | Option exercise | 1.00K | $179.25K |
Flow & Concentration
| Insider 180d net | -$24.17M |
|---|---|
| Insider buys / sells | 0 / 32 |
| Insider bias | Sellers |
| 13F holders | 8 |
| Top-5 share | 99.1% |
| HHI | 5,739 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Fidelity / FMR LLC | $1.64B | 4.42M |
| State Street Corp | $502.20M | 1.35M |
| Capital Research / Capital World | $60.22M | 162.02K |
| Renaissance Technologies | $22.18M | 59.68K |
| Bridgewater Associates | $20.25M | 54.49K |
| Citadel Advisors | $15.99M | 43.02K |
| AQR Capital Management | $5.20M | 14.00K |
| T. Rowe Price Group | $255.49K | 687.40K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2017–2025 · 7 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $389.13M | +33.9% | |
| Operating income | $65.75M | — | |
| Net income | $204.83M | — | |
| Cash from ops | -$88.80M | — |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $346.34 | $347.74 | $341.90 | $345.82 | 200.00K |
| Sep 24 | $341.85 | $345.48 | $336.56 | $344.96 | 222.50K |
| Sep 23 | $353.84 | $353.84 | $337.58 | $341.75 | 215.90K |
| Sep 22 | $334.76 | $353.83 | $334.31 | $350.88 | 274.50K |
| Sep 21 | $339.48 | $341.15 | $332.43 | $333.85 | 210.30K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →